2018 AANS Annual Scientific Meeting-505. Systemic and Local Immunosuppression In Patients With High-Grade Meningiomas

505. Systemic and Local Immunosuppression In Patients With High-Grade Meningiomas

Video Transcription

Video Summary

In this video, Derek Lee presents his research on systemic and local immunosuppression in patients with high-grade meningiomas. Meningiomas are the most common primary intracranial tumor. Lee discusses the potential use of immunotherapy to stimulate the immune system and target tumor cells. He explains that immune checkpoints, such as PD-1 and PD-L1, play a role in tumor evasion of the immune system. Lee presents findings from studies showing that PD-L1 is expressed in meningiomas, primarily by tumor cells. He also discusses his own study, which examines the extent of immunosuppression in meningiomas and the potential for immune checkpoint inhibitors as a treatment option. Overall, the data supports the use of immunomodulators in high-grade meningiomas.

Asset Caption

Yuping Derek Li

Keywords

systemic immunosuppression

local immunosuppression

high-grade meningiomas

immunotherapy

immune checkpoints